Our Technology
Engineering Fit-for-Purpose Biotherapeutics
Our technology leverages Zymeworks’ industry leading expertise in the fields of protein engineering and drug chemistry to discover and develop the next generation of antibody-based therapeutics to combat unmet medical need in hard-to-treat cancers and other serious diseases.
The integration of complementary and antibody-based technologies, embedded in our proprietary multispecific and antibody-drug conjugate (ADC) therapeutic modalities, interfaced with disease biology, enables the development of differentiated and fit-for-purpose therapeutics.
Select Difficult-to-Treat Cancers & Target
Design with Complementary Technology
Optionality with Two Foundational Fit-for-Purpose Modalities
Zymeworks is an industry leader in multispecific research and the use of this technology in developing therapeutics targeting areas of high unmet medical need.
Our clinically validated technologies harness the flexibility of our proprietary Azymetric™ platform as a foundation to solve biological challenges.
Explore our technologies
We are dedicated to the development of best in class or first in class ADC therapeutics that will make a real difference for people impacted by difficult to treat cancers and other diseases.
Our unique approach to the design and development of ADCs paired with our toolbox of protein engineering technologies and proprietary payloads provides us with the flexibility to precisely engineer and develop highly differentiated ADC therapeutics.
